Clinical trial
Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non Small Cell Lung Cancer (NSCLC) Patients.
NCT00905983 is registered in ClinicalTrials.gov with Hospital Arnau de Vilanova as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non Small Cell Lung Cancer (NSCLC) Patients.
- Lead sponsor
- Hospital Arnau de Vilanova
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 31, 2007
- Completion date
- September 30, 2011
- Enrollment
- 48 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.